BioCentury
ARTICLE | Clinical News

LJP 1082: Began Phase I/II trial

November 12, 2001 8:00 AM UTC

La Jolla Pharmaceutical Co. (LJPC), San Diego, Calif. Product: LJP 1082 Business: Autoimmune/Inflammation Therapeutic category: Immune modulation Target: Antibodies against beta 2 glycoprotein Descr...